Education
About Us
Working with TipRanks
Follow Us
Agios Pharmaceuticals (GB:0HB0)
:0HB0
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.81Last Year’s EPS
-1.69Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 1.93%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Agios demonstrates a strong financial position and significant progress in their pipeline, particularly with PYRUKYND. However, the decline in revenue and increased operating expenses present challenges. The overall sentiment is cautiously optimistic with an emphasis on future growth potential.Company Guidance
During Agios' first quarter 2025 conference call, the company provided guidance highlighting key financial and strategic metrics. Agios reported a strong balance sheet with approximately $1.4 billion in cash, which they believe will support financial independence for upcoming product launches and pipeline advancements. The company is preparing for a potential U.S. approval and launch of their lead product, PYRUKYND (mitapivat), for thalassemia by September 7, 2025, followed by sickle cell disease in 2026. Agios anticipates significant revenue growth, with PYRUKYND representing a multi-billion dollar opportunity across these indications. The commercial organization has been strategically expanded to support these launches, with a sales team doubled in size for thalassemia. Additionally, Agios is progressing multiple pipeline programs, including the Phase 2b study of tebapivat in low-risk MDS and a planned Phase 2 study in sickle cell disease, demonstrating their commitment to advancing their diverse portfolio while maintaining disciplined capital allocation.Strong Financial Position
Agios has approximately $1.4 billion in cash, ensuring financial independence to fund new approvals, product launches, and pipeline advancement.
PYRUKYND Commercialization Plans
Potential approval and launch of PYRUKYND for thalassemia in the U.S. are expected in September 2025, with sickle cell disease approval anticipated in 2026.
Positive Phase 3 Trial Results
Announced positive top-line results from The ACTIVATE-Kids Phase 3 trial and successful completion of enrollment for the Phase 3 RISE UP study.
Pipeline Advancements
Plans to complete enrollment in Phase 2b study for tebapivat in MDS and initiate a Phase 2 study in sickle cell disease by mid-2025.
Strategic Corporate Development
Hiring of Krishnan Viswanadhan as Chief Corporate Development and Strategy Officer to maximize asset potential and explore expansion opportunities.
GB:0HB0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0HB0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $29.30 | $29.30 | 0.00% |
Feb 13, 2025 | $32.51 | $32.35 | -0.49% |
Oct 31, 2024 | $46.36 | $44.89 | -3.17% |
Aug 01, 2024 | $47.04 | $43.83 | -6.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Agios Pharmaceuticals (GB:0HB0) report earnings?
Agios Pharmaceuticals (GB:0HB0) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Agios Pharmaceuticals (GB:0HB0) earnings time?
Agios Pharmaceuticals (GB:0HB0) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Agios Pharmaceuticals stock?
The P/E ratio of Agios Pharma is N/A.
What is GB:0HB0 EPS forecast?
GB:0HB0 EPS forecast for the fiscal quarter 2025 (Q2) is -1.81.